1	An	An	B-NP	DT	O	2	NMOD	-1
2	evaluation	evaluation	I-NP	NN	O	11	NMOD	-1
3	of	of	B-PP	IN	O	2	NMOD	-1
4	low	low	B-NP	JJ	O	7	NMOD	-1
5	molecular	molecular	I-NP	JJ	O	7	NMOD	-1
6	weight	weight	I-NP	NN	O	7	NMOD	-1
7	heparin	heparin	I-NP	NN	O	3	PMOD	-1
8	and	and	O	CC	O	11	NMOD	-1
9	hyperbaric	hyperbaric	B-NP	JJ	O	11	NMOD	-1
10	oxygen	oxygen	I-NP	NN	O	11	NMOD	-1
11	treatment	treatment	I-NP	NN	O	0	ROOT	19	treatment
12	in	in	B-PP	IN	O	11	NMOD	-1
13	the	the	B-NP	DT	O	14	NMOD	-1
14	prevention	prevention	I-NP	NN	O	12	PMOD	0
15	of	of	B-PP	IN	O	14	NMOD	-1
16	intra-abdominal	intra-abdominal	B-NP	JJ	O	17	NMOD	-1
17	adhesions	adhesion	I-NP	NNS	O	20	NMOD	-1
18	and	and	O	CC	O	20	NMOD	-1
19	wound	wound	B-NP	NN	O	20	NMOD	-1
20	healing	healing	I-NP	NN	O	15	PMOD	-1
21	.	.	O	.	O	11	P	-1

1	BACKGROUND	BACKGROUND	B-NP	NN	O	5	SUB	-1
2	:	:	O	:	O	1	P	-1
3	Abdominal	Abdominal	B-NP	JJ	O	4	NMOD	-1
4	surgery	surgery	I-NP	NN	O	5	SUB	0
5	can	can	B-VP	MD	O	0	ROOT	-1
6	lead	lead	I-VP	VB	O	5	VC	0
7	to	to	B-PP	TO	O	6	VMOD	-1
8	intra-abdominal	intra-abdominal	B-NP	JJ	O	9	NMOD	-1
9	adhesions	adhesion	I-NP	NNS	O	7	PMOD	-1
10	with	with	B-PP	IN	O	9	NMOD	-1
11	significant	significant	B-NP	JJ	O	14	NMOD	-1
12	morbidity	morbidity	I-NP	NN	O	14	NMOD	-1
13	and	and	I-NP	CC	O	14	NMOD	-1
14	mortality	mortality	I-NP	NN	O	10	PMOD	-1
15	.	.	O	.	O	5	P	-1

1	To	To	B-VP	TO	O	2	VMOD	-1
2	prevent	prevent	I-VP	VB	O	8	VMOD	0
3	adhesions	adhesion	B-NP	NNS	O	2	OBJ	-1
4	,	,	O	,	O	8	P	-1
5	an	an	B-NP	DT	O	7	NMOD	-1
6	experimental	experimental	I-NP	JJ	O	7	NMOD	-1
7	study	study	I-NP	NN	O	8	SUB	-1
8	was	be	B-VP	VBD	O	0	ROOT	-1
9	planned	plan	I-VP	VBN	O	8	VC	-1
10	to	to	I-VP	TO	O	11	VMOD	-1
11	designate	designate	I-VP	VB	O	9	VMOD	-1
12	the	the	B-NP	DT	O	13	NMOD	-1
13	effects	effect	I-NP	NNS	O	11	OBJ	0
14	of	of	B-PP	IN	O	13	NMOD	-1
15	low	low	B-NP	JJ	B-protein	21	NMOD	-1
16	molecular	molecular	I-NP	JJ	I-protein	21	NMOD	-1
17	weight	weight	I-NP	NN	I-protein	21	NMOD	-1
18	(	(	O	(	I-protein	21	NMOD	-1
19	LMW	LMW	B-NP	NN	I-protein	21	NMOD	-1
20	)	)	O	)	I-protein	21	NMOD	-1
21	heparins	heparin	B-NP	NNS	I-protein	14	PMOD	-1
22	and	and	O	CC	O	28	NMOD	-1
23	hyperbaric	hyperbaric	B-NP	JJ	O	24	NMOD	-1
24	oxygen	oxygen	I-NP	NN	O	28	NMOD	-1
25	(	(	O	(	O	27	DEP	-1
26	HBO	HBO	B-NP	NN	B-protein	27	DEP	-1
27	)	)	O	)	O	24	NMOD	-1
28	therapy	therapy	B-NP	NN	O	11	VMOD	19	therapy
29	both	both	B-PP	CC	O	28	NMOD	-1
30	on	on	B-PP	IN	O	29	PMOD	-1
31	the	the	B-NP	DT	O	32	NMOD	-1
32	formation	formation	I-NP	NN	O	30	PMOD	0
33	of	of	B-PP	IN	O	32	NMOD	-1
34	adhesions	adhesion	B-NP	NNS	O	37	NMOD	-1
35	and	and	O	CC	O	37	NMOD	-1
36	wound	wound	B-NP	NN	O	37	NMOD	-1
37	healing	healing	I-NP	NN	O	33	PMOD	-1
38	.	.	O	.	O	8	P	-1

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Thirty-eight	Thirty-eight	B-NP	CD	O	6	NMOD	-1
4	Wistar	Wistar	I-NP	NNP	O	6	NMOD	-1
5	albino	albino	I-NP	NNP	O	6	NMOD	-1
6	rats	rat	I-NP	NNS	O	7	SUB	-1
7	underwent	undergo	B-VP	VBD	O	1	NMOD	19	underwent
8	laparotomy	laparotomy	B-NP	NN	O	7	OBJ	-1
9	to	to	B-VP	TO	O	10	VMOD	-1
10	cause	cause	I-VP	VB	O	7	VMOD	-1
11	intra-abdominal	intra-abdominal	B-NP	JJ	O	12	NMOD	-1
12	adhesions	adhesion	I-NP	NNS	O	10	OBJ	-1
13	by	by	B-PP	IN	O	10	VMOD	-1
14	mechanical	mechanical	B-NP	JJ	O	15	NMOD	-1
15	abrasion	abrasion	I-NP	NN	O	13	PMOD	19	abrasion
16	of	of	B-PP	IN	O	15	NMOD	-1
17	the	the	B-NP	DT	O	21	NMOD	-1
18	cecum	cecum	I-NP	NN	O	21	NMOD	-1
19	and	and	I-NP	CC	O	21	NMOD	-1
20	ethanol	ethanol	I-NP	NN	O	21	NMOD	-1
21	application	application	I-NP	NN	O	16	PMOD	19	application
22	.	.	O	.	O	1	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	rats	rat	I-NP	NNS	O	3	SUB	-1
3	were	be	B-VP	VBD	O	0	ROOT	-1
4	divided	divide	I-VP	VBN	O	3	VC	-1
5	into	into	B-PP	IN	O	4	VMOD	-1
6	4	4	B-NP	CD	O	7	NMOD	-1
7	groups	group	I-NP	NNS	O	5	PMOD	-1
8	.	.	O	.	O	3	P	-1

1	In	In	B-PP	IN	O	12	VMOD	-1
2	the	the	B-NP	DT	O	4	NMOD	-1
3	control	control	I-NP	NN	O	4	NMOD	0
4	group	group	I-NP	NN	O	1	PMOD	-1
5	(	(	O	(	O	8	DEP	-1
6	group	group	B-NP	NN	O	8	DEP	-1
7	1	1	I-NP	CD	O	6	NMOD	-1
8	)	)	O	)	O	4	NMOD	-1
9	no	no	B-NP	DT	O	11	NMOD	-1
10	further	further	I-NP	JJ	O	11	NMOD	-1
11	management	management	I-NP	NN	O	12	SUB	-1
12	was	be	B-VP	VBD	O	0	ROOT	-1
13	undertaken	undertake	I-VP	VBN	O	12	VC	-1
14	.	.	O	.	O	12	P	-1

1	Group	Group	B-NP	NN	O	3	SUB	-1
2	2	2	I-NP	CD	O	1	NMOD	-1
3	was	be	B-VP	VBD	O	18	VMOD	-1
4	treated	treat	I-VP	VBN	O	3	VC	19	treated
5	by	by	B-PP	IN	O	4	VMOD	-1
6	Enoxaparine	Enoxaparine	B-NP	NN	O	7	NMOD	-1
7	Na	Na	I-NP	NN	O	9	NMOD	-1
8	,	,	O	,	O	9	P	-1
9	group	group	B-NP	NN	O	5	PMOD	-1
10	3	3	I-NP	CD	O	9	NMOD	-1
11	received	receive	B-VP	VBD	O	18	VMOD	0
12	HBO	HBO	B-NP	NN	O	13	NMOD	-1
13	therapy	therapy	I-NP	NN	O	11	OBJ	19	therapy
14	,	,	O	,	O	16	P	-1
15	and	and	O	CC	O	16	NMOD	-1
16	group	group	B-NP	NN	O	18	SUB	-1
17	4	4	I-NP	CD	O	16	NMOD	-1
18	was	be	B-VP	VBD	O	0	ROOT	-1
19	given	give	I-VP	VBN	O	18	VC	0
20	both	both	O	CC	O	25	NMOD	-1
21	enoxaparine	enoxaparine	B-NP	NN	O	22	NMOD	-1
22	Na	Na	I-NP	NN	O	25	NMOD	-1
23	and	and	O	CC	O	25	NMOD	-1
24	HBO	HBO	B-NP	NN	B-protein	25	NMOD	-1
25	treatment	treatment	I-NP	NN	O	19	OBJ	19	treatment
26	.	.	O	.	O	18	P	-1

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	-1
3	There	There	B-NP	EX	O	4	SUB	-1
4	was	be	B-VP	VBD	O	1	NMOD	-1
5	a	a	B-NP	DT	O	8	NMOD	-1
6	statistically	statistically	I-NP	RB	O	7	AMOD	-1
7	significant	significant	I-NP	JJ	O	8	NMOD	-1
8	difference	difference	I-NP	NN	O	4	PRD	-1
9	between	between	B-PP	IN	O	8	NMOD	-1
10	the	the	B-NP	DT	O	15	NMOD	-1
11	control	control	I-NP	NN	O	15	NMOD	0
12	and	and	I-NP	CC	O	15	NMOD	-1
13	enoxaparine	enoxaparine	I-NP	NN	O	15	NMOD	-1
14	Na	Na	I-NP	NN	O	15	NMOD	-1
15	groups	group	I-NP	NNS	O	17	NMOD	-1
16	regarding	regard	B-VP	VBG	O	17	NMOD	-1
17	adhesions	adhesion	B-NP	NNS	O	9	PMOD	-1
18	.	.	O	.	O	1	P	-1

1	Statistically	Statistically	B-NP	RB	O	3	NMOD	-1
2	significant	significant	I-NP	JJ	O	3	NMOD	-1
3	differences	difference	I-NP	NNS	O	4	SUB	-1
4	were	be	B-VP	VBD	O	0	ROOT	-1
5	observed	observe	I-VP	VBN	O	4	VC	0
6	between	between	B-PP	IN	O	5	VMOD	-1
7	groups	group	B-NP	NNS	O	6	PMOD	-1
8	1	1	I-NP	CD	O	10	NMOD	-1
9	and	and	I-NP	CC	O	10	NMOD	-1
10	4	4	I-NP	CD	O	7	NMOD	-1
11	and	and	O	CC	O	6	PMOD	-1
12	between	between	B-PP	IN	O	13	NMOD	-1
13	groups	group	B-NP	NNS	O	6	PMOD	-1
14	1	1	I-NP	CD	O	13	NMOD	-1
15	and	and	I-NP	CC	O	13	NMOD	-1
16	3	3	I-NP	CD	O	13	NMOD	-1
17	regarding	regard	B-VP	VBG	O	13	NMOD	-1
18	the	the	B-NP	DT	O	20	NMOD	-1
19	hydroxyproline	hydroxyproline	I-NP	NN	O	20	NMOD	-1
20	content	content	I-NP	NN	O	17	OBJ	-1
21	of	of	B-PP	IN	O	20	NMOD	-1
22	the	the	B-NP	DT	O	24	NMOD	-1
23	abdominal	abdominal	I-NP	JJ	O	24	NMOD	-1
24	wounds	wound	I-NP	NNS	O	21	PMOD	-1
25	.	.	O	.	O	4	P	-1

1	In	In	B-PP	IN	O	11	VMOD	-1
2	the	the	B-NP	DT	O	4	NMOD	-1
3	pathologic	pathologic	I-NP	JJ	O	4	NMOD	-1
4	analysis	analysis	I-NP	NN	O	1	PMOD	-1
5	of	of	B-PP	IN	O	4	NMOD	-1
6	the	the	B-NP	DT	O	8	NMOD	-1
7	abdominal	abdominal	I-NP	JJ	O	8	NMOD	-1
8	wounds	wound	I-NP	NNS	O	5	PMOD	-1
9	,	,	O	,	O	11	P	-1
10	there	there	B-NP	EX	O	11	SUB	-1
11	was	be	B-VP	VBD	O	0	ROOT	-1
12	no	no	B-NP	DT	O	15	NMOD	-1
13	statistically	statistically	I-NP	RB	O	14	AMOD	-1
14	significant	significant	I-NP	JJ	O	15	NMOD	-1
15	difference	difference	I-NP	NN	O	28	NMOD	-1
16	between	between	B-PP	IN	O	15	NMOD	-1
17	any	any	B-NP	DT	O	16	PMOD	-1
18	of	of	B-PP	IN	O	17	NMOD	-1
19	the	the	B-NP	DT	O	20	NMOD	-1
20	groups	group	I-NP	NNS	O	18	PMOD	-1
21	,	,	O	,	O	15	P	-1
22	including	include	B-PP	VBG	O	15	NMOD	-1
23	the	the	B-NP	DT	O	25	NMOD	-1
24	control	control	I-NP	NN	O	25	NMOD	0
25	group	group	I-NP	NN	O	22	PMOD	-1
26	,	,	O	,	O	15	P	-1
27	regarding	regard	B-VP	VBG	O	28	NMOD	-1
28	inflammation	inflammation	B-NP	NN	O	11	PRD	-1
29	.	.	O	.	O	11	P	-1

1	Statistically	Statistically	B-NP	RB	O	4	VMOD	-1
2	significant	significant	I-NP	JJ	O	3	NMOD	-1
3	differences	difference	I-NP	NNS	O	4	SUB	-1
4	were	be	B-VP	VBD	O	0	ROOT	-1
5	observed	observe	I-VP	VBN	O	4	VC	0
6	regarding	regard	B-PP	VBG	O	5	VMOD	-1
7	angiogenesis	angiogenesis	B-NP	NN	O	6	PMOD	3	angiogenesis
8	between	between	B-PP	IN	O	7	NMOD	-1
9	the	the	B-NP	DT	O	11	NMOD	-1
10	control	control	I-NP	NN	O	11	NMOD	0
11	group	group	I-NP	NN	O	13	NMOD	-1
12	and	and	O	CC	O	13	NMOD	-1
13	groups	group	B-NP	NNS	O	8	PMOD	-1
14	3	3	B-NP	CD	O	13	NMOD	-1
15	and	and	I-NP	CC	O	13	NMOD	-1
16	4	4	I-NP	CD	O	13	NMOD	-1
17	.	.	O	.	O	4	P	-1

1	There	There	B-NP	EX	O	2	SUB	-1
2	was	be	B-VP	VBD	O	0	ROOT	-1
3	also	also	B-ADVP	RB	O	2	VMOD	-1
4	a	a	B-NP	DT	O	7	NMOD	-1
5	statistically	statistically	I-NP	RB	O	6	AMOD	-1
6	significant	significant	I-NP	JJ	O	7	NMOD	-1
7	difference	difference	I-NP	NN	O	2	VMOD	-1
8	regarding	regard	B-VP	VBG	O	7	NMOD	-1
9	fibrosis	fibrosis	B-NP	NN	O	8	PMOD	-1
10	between	between	B-PP	IN	O	9	NMOD	-1
11	groups	group	B-NP	NNS	O	10	PMOD	-1
12	1	1	I-NP	CD	O	14	NMOD	-1
13	and	and	I-NP	CC	O	14	NMOD	-1
14	4	4	I-NP	CD	O	11	NMOD	-1
15	.	.	O	.	O	2	P	-1

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	12	SUB	-1
2	:	:	O	:	O	1	P	-1
3	Enoxaparine	Enoxaparine	B-NP	NN	O	4	NMOD	-1
4	Na	Na	I-NP	NN	O	5	SUB	-1
5	decreased	decrease	B-VP	VBD	O	12	VMOD	0
6	intra-abdominal	intra-abdominal	B-NP	JJ	O	7	NMOD	-1
7	adhesions	adhesion	I-NP	NNS	O	5	OBJ	-1
8	,	,	O	,	O	12	P	-1
9	and	and	O	CC	O	11	NMOD	-1
10	HBO	HBO	B-NP	NN	B-protein	11	NMOD	-1
11	therapy	therapy	I-NP	NN	O	12	SUB	19	therapy
12	had	have	B-VP	VBD	O	0	ROOT	-1
13	no	no	B-NP	DT	O	15	NMOD	-1
14	beneficial	beneficial	I-NP	JJ	O	15	NMOD	-1
15	effect	effect	I-NP	NN	O	12	OBJ	0
16	on	on	B-PP	IN	O	12	VMOD	-1
17	adhesions	adhesion	B-NP	NNS	O	16	PMOD	-1
18	.	.	O	.	O	12	P	-1

1	Enoxaparine	Enoxaparine	B-NP	NN	O	2	NMOD	-1
2	Na	Na	I-NP	NN	O	3	SUB	-1
3	had	have	B-VP	VBD	O	14	VMOD	-1
4	no	no	B-NP	DT	O	6	NMOD	-1
5	harmful	harmful	I-NP	JJ	O	6	NMOD	-1
6	effects	effect	I-NP	NNS	O	3	OBJ	0
7	on	on	B-PP	IN	O	3	VMOD	-1
8	wound	wound	B-NP	NN	O	9	NMOD	-1
9	healing	healing	I-NP	NN	O	7	PMOD	-1
10	,	,	O	,	O	14	P	-1
11	and	and	O	CC	O	14	VMOD	-1
12	HBO	HBO	B-NP	NN	B-protein	13	NMOD	-1
13	therapy	therapy	I-NP	NN	O	14	SUB	19	therapy
14	increased	increase	B-VP	VBD	O	0	ROOT	0
15	the	the	B-NP	DT	O	16	NMOD	-1
16	process	process	I-NP	NN	O	14	OBJ	-1
17	of	of	B-PP	IN	O	16	NMOD	-1
18	wound	wound	B-NP	NN	O	19	NMOD	-1
19	healing	healing	I-NP	NN	O	17	PMOD	-1
20	.	.	O	.	O	14	P	-1

